key: cord-1001187-xlbev1po
authors: Nusrat, Sanober; Borogovac, Azra; George, James N.; Curtis, Brian R.; Reese, Jessica A.
title: Drug (vaccine)‐induced thrombocytopenia 2021: Diversity of pathogenesis and clinical features
date: 2022-02-15
journal: Am J Hematol
DOI: 10.1002/ajh.26482
sha: c467145029f57c6611ce014c9fb023397e1617c1
doc_id: 1001187
cord_uid: xlbev1po

nan

Pembrolizumab (9) Nivolumab/Ipilimumab (6) Ipilimumab (2) Nivolumab/Pembrolizumab (1) Durvalumab (2) a Citations for the reports of these five drugs are in Table S1 . 

None.

Dr. Curtis is a consultant for Argenx, Ionis, and Rallybio pharmaceuticals. The other four authors have no conflicts of interest or financial conflicts with this study.

This study involved no human or animal subjects and required no Institutional Review Board approval.

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation

Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene

Drug-induced immune thrombocytopenia

Drug-induced thrombocytopenia: a systematic review of published case reports

Development of thrombocytopenia is associated with improved survival in patients treated with immunotherapy

Immune-related adverse events associated with immune checkpoint blockade

Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drugdependent antibodies

ORCID James N. George https://orcid.org/0000-0002-4243-2691Jessica A. Reese https://orcid.org/0000-0002-6640-6543